Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 3/20 | 0.49 |
| ▸ | DRD4 | P21917 | 3/20 | 0.49 |
| ▸ | DRD3 | P35462 | 3/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.48 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL320746 | 0.90 | RORC (0.55) | SIGMAR1KMT2ASLC6A4SLC6A3RORC | |
| SCHEMBL10277776 | 0.90 | RORC (0.55) | SIGMAR1KMT2ASLC6A4SLC6A3RORC | |
| SCHEMBL10277774 | 0.90 | RORC (0.55) | SIGMAR1KMT2ASLC6A4SLC6A3RORC | |
| SCHEMBL7818044 | 0.89 | SLC6A2 (0.56) | SLC6A4SLC6A3RORCSLC6A2MCHR1 | |
| SCHEMBL3072901 | 0.88 | DRD2 (0.46) | SIGMAR1DRD2DRD4DRD3RORC | |
| SCHEMBL7915812 | 0.83 | DRD2 (0.50) | SIGMAR1DRD2DRD4 | |
| SCHEMBL7914327 | 0.83 | DRD2 (0.50) | SIGMAR1DRD2DRD4 | |
| SCHEMBL3115936 | 0.83 | DRD2 (0.50) | SIGMAR1DRD2DRD4 | |
| SCHEMBL6042760 | 0.79 | SLC18A3 (0.57) | SIGMAR1KMT2ADRD2 | |
| SCHEMBL23417389 | 0.78 | F10 (0.54) | SLC6A4SLC6A3RORCSLC6A2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795436-B2 | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-14 | — | — | US | disclosed |
| US-20070049613-A1 | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049613-A1 | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists | HTR2B, HTR2C, HTR1A | SIGMAR1 149/4885KMT2A 3546/4885DRD2 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.